弥漫性大B细胞淋巴瘤IL-6和VEGF表达水平与化疗耐药的相关性

目的探讨弥漫性大B细胞淋巴瘤(DLBCL)患者血清白细胞介素6(IL-6)、血管内皮生长因子(VEGF)的表达及与化疗耐药之间的相关性。方法采用酶联免疫吸附试验(ELISA)分别测定16例化疗耐药患者(化疗耐药组)、20例化疗敏感患者(化疗敏感组)治疗前后和15例健康者(对照组)血清IL-6、VEGF水平。结果化疗耐药组患者血清IL-6、VEGF初治前表达水平明显高于化疗敏感组患者初治前和对照组(P<0.05),治疗缓解后明显低于治疗前(P<0.05)。DLBCL复发耐药时,患者血清中的IL-6、VEGF又高于缓解时水平(P<0.05)。化疗耐药组Ⅲ～Ⅳ期患者治疗前、复发耐药时IL-6、VEGF水平明显高于Ⅰ～Ⅱ期患者(P<0.05)。结论 DLBCL患者血清IL-6、VEGF表达水平的变化,提示其可以作为观察DLBCL病情变化的检测指标,可能与DLBCL细胞耐药有关。

Correlation between expression levels of cytokines IL-6 and VEGF with chemotherapy resistance in diffuse large B-cell lymphoma

Objective To investigate the correlation between expression levels of serum cytokines IL-6 and VEGF in the patients with diffuse large B-cell lymphoma(DLBCL) and chemotherapy resistance.Methods The levels of serum IL-6 and VEGF were measured by ELISA in 16 patients with chemotherapy resistance and 20 cases with chemotherapy-sensitive before and after treatment,and 15 healthy people(control group).Results The expression levels of serum IL-6 and VEGF before treatment in DLBCL patients with chemotherapy resistance were significantly higher than those in DLBCL patients with chemotherapy sensitive and the normal control group(P<0.05),however,which after treatment in DLBCL patients with chemotherapy resistance were significantly lower than those of before treatment(P<0.05).The levels of serum IL-6 and VEGF in patients with DLBCL recurrence to drug resistance were higher than those during remission(P<0.05).Before treatment,the expression level of serum IL6,VEGF in the patients with Ⅲ-Ⅳ stage in chemotherapy resistant group was significantly higher than that in ones with Ⅰ-Ⅱ stage(P <0.05).Conclusion The change of the expression levels of serum IL-6,VEGF in DLBCL patients could be considered as the detective markers for condition observation,and may be involved in drug resistance of DLBCL.